Health Economics & Outcomes Research
Real World Evidence Research
Patient Centered Outcomes Research
Late Stage Clinical Trials
Adjunct Instructor
Research & Practice Interests
Education
PhD, Queen's University, Kingston, Ontario, Canada
MSc, Queen's University, Kingston, Ontario, Canada
BScH, Queen's University, Kingston, Ontario, Canada
Publications
- Change in urine albumin-to-creatinine ratio and clinical outcomes in patients with chronic kidney disease and type 2 diabetes
- Changes in urine albumin-to-creatinine ratio and health care resource utilization and costs in patients with type 2 diabetes and chronic kidney disease
- Guideline-directed medical therapies (GDMTs) for chronic kidney disease with type 2 diabetes (CKD + T2D): Translation of lessons learned from the management of heart failure
- Transforming Traditional Industry Advisory Boards Into Mutually Beneficial Strategic Think Tanks: A Peer Review Council Case Series and Best Practices
- Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States
TEACHING
Applied Health Economics & Outcomes Research
Biography
Dr. Williamson brings over 30 years of experience as a scientific researcher in the pharmaceutical industry with extensive experience in health economics, real world, and clinical studies. He has deep experience across multiple disease categories with significant experience in both oncology and rare disease and over 20 years in leadership positions with research teams under his remit. In his most current role as the Vice President of Data Generation and Observational Studies at Bayer, he was responsible for leading a team to identify gaps in research for pharmaceuitical compounds, both in the developmental and post approval stages, leading the execution and publication of research expanding the documented benefits of these compounds beyon that of registration trials into the real-world setting.
Dr. Williamson is an expert in health economics and outcomes research, real-world clinical studies, and research in oncology and rare diseases. This includes the continued evolution of the methodology behind health economics as this research continues to evolve and establish standards and credibility in the field of research science. He has worked extensively in modeling research to be able to document the long-tem impacts of treatments for certain conditions well beyond that of the limited timeframe of traditional clinical trial research.